Tag Archives: HER2-Positive

Roche’s Kadcyla Demonstrates Long-Term Survival Benefit in HER2-Positive Early Breast Cancer

Posted on 9, December 2023 by

(IN BRIEF) Roche has released positive long-term follow-up data from the Phase III KATHERINE study, evaluating Kadcyla® (trastuzumab emtansine) as adjuvant therapy for people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant treatment. The study … Read the full press release →

Posted in Business, Healthcare, Industrial, Management, News, Science, Switzerland, Technology

Tagged , , , , , , ,